KYNB
Kyntra Bio, Inc.
NASDAQ: KYNB · HEALTHCARE · BIOTECHNOLOGY
$7.27
+3.12% today
Updated 2026-04-30
Market cap
$28.37M
P/E ratio
—
P/S ratio
4.41x
EPS (TTM)
$-14.40
Dividend yield
—
52W range
$5 – $13
Volume
0.0M
Kyntra Bio, Inc. (KYNB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.93M | $102.17M | $137.60M | $180.83M | $179.58M | $125.67M | $212.96M | $256.58M | $176.32M | $235.31M | $140.73M | $46.80M | $29.62M | $6.44M |
| Revenue growth (YoY) | — | +55.0% | +34.7% | +31.4% | -0.7% | -30.0% | +69.5% | +20.5% | -31.3% | +33.5% | -40.2% | -66.7% | -36.7% | -78.3% |
| Cost of revenue | $74.22M | $85.71M | $150.79M | $214.09M | $187.21M | $196.52M | $235.84M | $1.15M | $8.87M | $449.19M | $20.28M | $3.96M | $15.56M | $556000.00 |
| Gross profit | $-8.29M | $16.46M | $-13.19M | $-33.26M | $-7.63M | $-70.85M | $-22.88M | $255.43M | $167.45M | $-213.88M | $120.45M | $42.84M | $14.06M | $5.88M |
| Gross margin | -12.6% | 16.1% | -9.6% | -18.4% | -4.2% | -56.4% | -10.7% | 99.6% | 95.0% | -90.9% | 85.6% | 91.5% | 47.5% | 91.4% |
| R&D | $74.22M | $85.71M | $150.79M | $214.09M | $187.21M | $196.52M | $235.84M | $209.26M | $252.92M | $387.04M | $296.79M | $266.47M | $95.69M | $23.52M |
| SG&A | $18.93M | $24.41M | $36.91M | $44.36M | $46.02M | $51.76M | $63.81M | — | — | $123.92M | $124.69M | $86.48M | $49.33M | $27.71M |
| Operating income | $-27.22M | $-7.95M | $-50.10M | $-77.63M | $-53.65M | $-122.61M | $-86.69M | $-89.31M | $-191.88M | $-288.53M | $-301.02M | $-322.72M | $-150.42M | $-45.90M |
| Operating margin | -41.3% | -7.8% | -36.4% | -42.9% | -29.9% | -97.6% | -40.7% | -34.8% | -108.8% | -122.6% | -213.9% | -689.5% | -507.8% | -712.7% |
| EBITDA | $-17.05M | $843000.00 | $-43.93M | $-68.83M | $-44.99M | $-104.75M | $-68.56M | $-52.31M | $-164.28M | $-333.72M | $-282.82M | $-305.20M | $-142.43M | $-45.90M |
| EBITDA margin | -25.9% | 0.8% | -31.9% | -38.1% | -25.1% | -83.4% | -32.2% | -20.4% | -93.2% | -141.8% | -201.0% | -652.1% | -480.8% | -712.7% |
| EBIT | $-22.64M | $-4.24M | $-48.40M | $-74.50M | $-51.03M | $-110.85M | $-75.13M | $-73.77M | $-186.33M | $-348.53M | $-293.43M | $-315.13M | $-145.12M | $-46.64M |
| Interest expense | $10.03M | $10.70M | $11.11M | $11.03M | $10.72M | $9.71M | $10.99M | $2.88M | $2.40M | $1.07M | $1.44M | $8.10M | $8.25M | $8.76M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-32.57M | $-14.94M | $-59.50M | $-85.78M | $-61.68M | $-126.20M | $-86.42M | $-76.97M | $-189.29M | $-290.02M | $-293.65M | $-284.23M | $-47.58M | $183.45M |
| Net income growth (YoY) | — | +54.1% | -298.2% | -44.2% | +28.1% | -104.6% | +31.5% | +10.9% | -145.9% | -53.2% | -1.3% | +3.2% | +83.3% | +485.6% |
| Profit margin | -49.4% | -14.6% | -43.2% | -47.4% | -34.3% | -100.4% | -40.6% | -30.0% | -107.4% | -123.3% | -208.7% | -607.3% | -160.6% | 2848.6% |